Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.51 |
| ▸ | RAB9A | P51151 | 9/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497810 | 0.80 | NPBWR1 (0.65) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL4814783 | 0.79 | RAB9A (0.60) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL2308775 | 0.79 | NPBWR1 (0.79) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL2053008 | 0.79 | AMY1A (0.41) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL5566197 | 0.79 | NPC1 (0.78) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL28761269 | 0.78 | RAB9A (0.80) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL4487881 | 0.77 | MMP2 (0.66) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL27846436 | 0.76 | CYP1A2 (0.56) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL2967008 | 0.76 | NPBWR1 (0.57) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL5204081 | 0.76 | F7 (0.54) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362072-B2 | BRCA1-based breast or ovarian cancer treatment agents and methods of use | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362072-B2 | BRCA1-based breast or ovarian cancer treatment agents and methods of use | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | UNIVERSITY OF KANSAS (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | UNIVERSITY OF KANSAS (US) | 2012-10-11 | — | — | US | disclosed |
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | MAKOVEC FRANCESCO | 2010-05-13 | — | — | US | disclosed |
| US-7674809-B2 | Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM S.P.A. (IT) | 2010-03-09 | — | — | US | disclosed |
| US-20090170842-A1 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | UNIVERSITY OF KANSAS (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170842-A1 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | UNIVERSITY OF KANSAS (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2009065028-A2 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | UNIVERSITY OF KANSAS (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | NOS3, NOS1, NOS2 | NPBWR1 323/4885RAB9A 2198/4885MAPT 4542/4885 |
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | BRCA1, BRAP, BCCIP | NPBWR1 1767/4885RAB9A 2880/4885MAPT 3769/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | NPBWR1 323/4885RAB9A 2198/4885MAPT 4542/4885 |
| US-20090170842-A1 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | BRCA1, BRAP, BCCIP | NPBWR1 1769/4885RAB9A 2889/4885MAPT 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.